Seladelpar Achieves Primary, Secondary Endpoints in Phase 3 RESPONSE Trial
Results from RESPONSE show seladelpar may improve measures of disease activity and reduce symptom burden in patients with PBC.
Source: hcplive.com
Page 14 - Phase 3 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Phase 3. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Phase 3 Today - Breaking & Trending Today
ROSEN, TRUSTED INVESTOR COUNSEL, FIRM Encourages Rain
NEW YORK, Aug. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology...
Source: globenewswire.com
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration (NMPA)Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpointData from EXPLORER-CN trial to be presented in an oral late-breaking science session at European Society of Cardiology Congress 2023Cash, cash equivalents and marketable securities of $267.3 million with runway into the first half of 2025
Source: yahoo.com
Vistagen Announces Topline Phase 3 PALISADE-2 Trial Results Of Fasedienol, Stock Up
Shares of Vistagen Therapeutics, Inc. (VTGN) rose by 713% on Monday due to the company's announcement of positive topline results from the Phase 3 PALISADE-2 trial.
Source: rttnews.com
Gilead scraps phase 3 trial of blood cancer treatment
Gilead Sciences has decided to end a phase 3 trial of magrolimab for higher-risk myelodysplastic syndromes (MDS) after an analysis suggested it would be futile to continue.
Source: biopharma-reporter.com